Robyn P Hickerson1,2, Tycho J Speaker1, Maria Fernanda Lara1,3, Emilio González-González4,5,6, Manuel A Flores1, Christopher H Contag4,5,7,8, Roger L Kaspar9. 1. TransDerm Inc., 2161 Delaware Ave., Santa Cruz, CA, 95060, USA. 2. Centre for Dermatology and Genetic Medicine, University of Dundee, Dundee, UK. 3. Urology Research Unit Virgen de la Victoria and Regional Hospital, Malaga, Spain. 4. Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, CA, USA. 5. Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. 6. Canvax Biotech S.L., Technological Park, Cordoba, Spain. 7. Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA. 8. Departments of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. 9. TransDerm Inc., 2161 Delaware Ave., Santa Cruz, CA, 95060, USA. roger.kaspar@transderminc.com.
Abstract
PURPOSE: Small interfering RNAs (siRNAs) specifically and potently inhibit target gene expression. Pachyonychia congenita (PC) is a skin disorder caused by mutations in genes encoding keratin (K) 6a/b, K16, and K17, resulting in faulty intermediate filaments. A siRNA targeting a single nucleotide, PC-relevant mutation inhibits K6a expression and has been evaluated in the clinic with encouraging results. PROCEDURES: To better understand the pathophysiology of PC, and develop a model system to study siRNA delivery and visualize efficacy in skin, wild type (WT) and mutant K6a complementary DNAs (cDNAs) were fused to either enhanced green fluorescent protein or tandem tomato fluorescent protein cDNA to allow covisualization of mutant and WT K6a expression in mouse footpad skin using a dual fluorescence in vivo confocal imaging system equipped with 488 and 532 nm lasers. RESULTS: Expression of mutant K6a/reporter resulted in visualization of keratin aggregates, while expression of WT K6a/reporter led to incorporation into filaments. Addition of mutant K6a-specific siRNA resulted in inhibition of mutant, but not WT, K6a/reporter expression. CONCLUSIONS: Intravital imaging offers subcellular resolution for tracking functional activity of siRNA in real time and enables detailed analyses of therapeutic effects in individual mice to facilitate development of nucleic acid-based therapeutics for skin disorders.
PURPOSE: Small interfering RNAs (siRNAs) specifically and potently inhibit target gene expression. Pachyonychia congenita (PC) is a skin disorder caused by mutations in genes encoding keratin (K) 6a/b, K16, and K17, resulting in faulty intermediate filaments. A siRNA targeting a single nucleotide, PC-relevant mutation inhibits K6a expression and has been evaluated in the clinic with encouraging results. PROCEDURES: To better understand the pathophysiology of PC, and develop a model system to study siRNA delivery and visualize efficacy in skin, wild type (WT) and mutant K6a complementary DNAs (cDNAs) were fused to either enhanced green fluorescent protein or tandem tomato fluorescent protein cDNA to allow covisualization of mutant and WT K6a expression in mouse footpad skin using a dual fluorescence in vivo confocal imaging system equipped with 488 and 532 nm lasers. RESULTS: Expression of mutant K6a/reporter resulted in visualization of keratin aggregates, while expression of WT K6a/reporter led to incorporation into filaments. Addition of mutant K6a-specific siRNA resulted in inhibition of mutant, but not WT, K6a/reporter expression. CONCLUSIONS: Intravital imaging offers subcellular resolution for tracking functional activity of siRNA in real time and enables detailed analyses of therapeutic effects in individual mice to facilitate development of nucleic acid-based therapeutics for skin disorders.
Entities:
Keywords:
Gene regulation; Gene therapy; Genodermatosis; In vivo confocal fluorescence microscopy
Authors: Deena M Leslie Pedrioli; Dun Jack Fu; Emilio Gonzalez-Gonzalez; Christopher H Contag; Roger L Kaspar; Frances J D Smith; W H Irwin McLean Journal: J Invest Dermatol Date: 2012-03-08 Impact factor: 8.551
Authors: Maria Fernanda Lara; Emilio González-González; Tycho J Speaker; Robyn P Hickerson; Devin Leake; Leonard M Milstone; Christopher H Contag; Roger L Kaspar Journal: Hum Gene Ther Date: 2012-06-05 Impact factor: 5.695
Authors: Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar Journal: Mol Ther Date: 2009-11-24 Impact factor: 11.454
Authors: Robyn P Hickerson; Frances J D Smith; Robert E Reeves; Christopher H Contag; Devin Leake; Sancy A Leachman; Leonard M Milstone; W H Irwin McLean; Roger L Kaspar Journal: J Invest Dermatol Date: 2007-10-11 Impact factor: 8.551
Authors: Qian Wang; Heini Ilves; Pauline Chu; Christopher H Contag; Devin Leake; Brian H Johnston; Roger L Kaspar Journal: J Invest Dermatol Date: 2007-05-24 Impact factor: 8.551
Authors: Edwin H A Allen; Sarah D Atkinson; Haihui Liao; Jonathan E Moore; Deena M Leslie Pedrioli; Frances J D Smith; W H Irwin McLean; C B Tara Moore Journal: Invest Ophthalmol Vis Sci Date: 2013-01-17 Impact factor: 4.799
Authors: Emilio González-González; Yeu-Chun Kim; Tycho J Speaker; Robyn P Hickerson; Ryan Spitler; James C Birchall; Maria Fernanda Lara; Rong-Hua Hu; Yanhua Liang; Nancy Kirkiles-Smith; Mark R Prausnitz; Leonard M Milstone; Christopher H Contag; Roger L Kaspar Journal: Sci Rep Date: 2011-11-15 Impact factor: 4.379
Authors: Frances J D Smith; Robyn P Hickerson; Jane M Sayers; Robert E Reeves; Christopher H Contag; Devin Leake; Roger L Kaspar; W H Irwin McLean Journal: J Invest Dermatol Date: 2007-08-30 Impact factor: 8.551
Authors: Jingyuan Sun; Vincent E Groppi; Honglian Gui; Lu Chen; Qing Xie; Li Liu; M Bishr Omary Journal: Methods Enzymol Date: 2015-11-19 Impact factor: 1.600